Clinical data | |
---|---|
Trade names | Methergine |
AHFS/Drugs.com | International Drug Names |
MedlinePlus | a601077 |
Pregnancy category |
|
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Biological half-life | 30–120 min |
Excretion | Mostly bile |
Identifiers | |
|
|
Synonyms | Methylergobasine Methylergobrevin Methylergonovine |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.003.661 |
Chemical and physical data | |
Formula | C20H25N3O2 |
Molar mass | 339.432 g/mol |
3D model (Jmol) | |
Melting point | 172 °C (342 °F) |
Solubility in water | insoluble mg/mL (20 °C) |
|
|
|
|
(what is this?) |
Methylergometrine (also called methylergonovine, methylergobasin, and D-lysergic acid 1-butanolamide) is a synthetic analogue of ergonovine, a psychedelic alkaloid found in ergot, and many species of morning glory. It is a member of the ergoline family and chemically similar to LSD, ergine, ergometrine, and lysergic acid. Due to its properties, it has a medical use in obstetrics. According to Jonathan Ott, methylergonovine has LSD-like actions above 2 milligrams, due to its agonistic action at the 5HT2A-mGlu2 receptor protomers. Clinical efficacy occurs around 200 µg, ten times lower than the hallucinogenic threshold.
Methylergometrine maleate is marketed under the trade name Methergine.
Methylergometrine is a smooth muscle constrictor that mostly acts on the uterus. It is most commonly used to prevent or control excessive bleeding following childbirth and spontaneous or elective abortion, and also to aid in expulsion of retained products of conception after a missed abortion (miscarriage in which all or part of the fetus remains in the uterus) and to help deliver the placenta after childbirth. It is available as tablets or injection (IM or IV) or in liquid form to be taken orally.